Ireland
--:--IST
Starting soon Not applicable

Radicle Energy VBMTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes

NCT07653724 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2026-06-25
Last updated
2026-06-17

Condition(s) studied

FatigueCognitive FunctionGlobal Mental HealthSleep Disturbance

Investigational drug(s) / intervention(s)

Energy Product Placebo ControlEnergy Active Product 1

Energy Product Placebo Control: Participants will use their Energy Product Placebo Control as directed for a period of 6 weeks.

Energy Active Product 1: Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.

Study summary

Radicle Energy VBMTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes.

Eligibility

Sex
ALL
Min age
21 Years
Max age
105 Years
Healthy volunteers
Accepted
Participants must meet all the following criteria: * Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities * Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed * Resides in the United States * Has the opportunity for at least 30% improvement in their primary health outcome * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study 3.2 Exclusion Individuals who report any of the following during screening may be excluded from participation: * Report being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address and mobile phone number * Reports current enrollment in another clinical trial * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English at a 7th grade level * Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk. * Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure * Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products * Reports current use of caffeine-alternative products * Reports consuming 3 or more caffeinated beverages a day * Lack of reliable daily access to the internet

Primary outcome measure(s)

  • Change in fatigue — 7 weeks
    Change in fatigue: Difference in rates of change over time in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)

Trial sites (1)

FacilityCityRegionStatus
Radicle Science Inc. Del Mar California
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07653724 on ClinicalTrials.gov ↗ ← All trials in the USA